LENZ Therapeutics, Inc. $LENZ Shares Purchased by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ raised its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 99.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 185,642 shares of the company’s stock after acquiring an additional 92,362 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in LENZ Therapeutics were worth $8,647,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bfsg LLC acquired a new stake in shares of LENZ Therapeutics during the third quarter valued at $30,000. Osaic Holdings Inc. lifted its holdings in LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after purchasing an additional 1,116 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of LENZ Therapeutics by 51.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock worth $41,000 after purchasing an additional 477 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of LENZ Therapeutics by 9,235.3% during the third quarter. SBI Securities Co. Ltd. now owns 1,587 shares of the company’s stock worth $74,000 after buying an additional 1,570 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of LENZ Therapeutics by 47.6% during the second quarter. Ameritas Investment Partners Inc. now owns 1,817 shares of the company’s stock worth $53,000 after buying an additional 586 shares in the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics Trading Down 2.1%

LENZ opened at $12.77 on Thursday. LENZ Therapeutics, Inc. has a twelve month low of $12.48 and a twelve month high of $50.40. The firm has a market cap of $399.57 million, a price-to-earnings ratio of -6.05 and a beta of 0.50. The company has a fifty day simple moving average of $16.64 and a 200 day simple moving average of $28.86.

Analyst Ratings Changes

LENZ has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research downgraded shares of LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $56.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.